article thumbnail

Need investment capital?

Berkonomics

Preparing for the game… If you have been following our recent insights, you’ll be up to speed knowing that professional investors negotiate tough terms, from provisions of control over asset acquisition, eventual sale of the company, future investments, forced co-sale when others attempt to sell their shares and more.

Invest 296
article thumbnail

You name the price; I’ll name the terms.

Berkonomics

The rest of the purchase price was concocted from a brew of zero-coupon bonds (where the face value is many times the invested amount until the reduced cost bonds mature thirty years later), and borrowing using the target company’s accounts receivable and other assets as collateral for a loan to purchase the company. What power!

Pricing 156
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GoodRx Prices IPO

socalTECH

Santa Monica-based prescription and healthcare marketplace operator GoodRx has priced its IPO, saying late last night that it is offering up 34,615,384 shares of its Class A common stock at $33.00 The company priced well above its initial offering range, which was $24.00 per share, indicating high investor interst in the company.

Pricing 113
article thumbnail

Avidity Biosciences Prices IPO

socalTECH

San Diego-based Avidity Bio , a biopharmaceuticals company working on oligonucleotide-based therapies, priced its IPO last night, saying that it will offer up 14,400,000 shares of its common stock at $18.00 The company priced above its initial estimated offering range of $14.00 READ MORE>>.

Pricing 113
article thumbnail

GoodRx Sets IPO Pricing Range

socalTECH

Santa Monica-based GoodRx , a developer of a digital healthcare and prescriptions service, has set an IPO pricing range of between $24.00 and $28.00 The company is looking to raise as much as $1.1 billion through its IPO on the NASDAQ Global Select Market. GoodRx has filed to trade as GDRX. Morgan Stanley, Goldman Sachs & Co.

article thumbnail

Avidity Biosciences Sets IPO Pricing Range

socalTECH

La Jolla-based Avidity Biosciences , which is developing oligonucleotide-based therapies for rare and serious diseases, has set the pricing range for its IPO, saying it is looking to sell 10 million shares at between $14.00 and $16.00 The company said it has applied to list on the Nasdaq Global Market as RNA.

Pricing 113
article thumbnail

AnaptysBio Sets Estimated IPO Pricing Range

socalTECH

San Diego-based AnaptysBio , which develops antibodies for treating inflammation, has set its estimated IPO pricing range, saying on Tuesday that it expects to price its IPO at between $14.00 and $16.00 The company is selling 4,000,000 shares of its common stock on the NASDAQ Global Select Market as ANAB. as early as Thursday.

Pricing 100